Tags

Type your tag names separated by a space and hit enter

De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
Clin Transplant 1994; 8(4):388-95CT

Abstract

We compared the incidence of de novo tumors developing in 1165 primary adult renal allograft recipients treated with azathioprine (AZA)-prednisone (Pred)-antilymphocyte globulin (ALG) (CONV group) with that in 722 patients receiving cyclosporine (CSA) as part of double (CSA-Pred), triple (CSA-Pred-AZA), or quadruple-therapy (CSA-Pred-AZA-ALG) protocols. Mean +/- SD follow-up was 9.5 +/- 6.4 years for the CONV group and 6.2 +/- 2.7 years for the CSA group. Overall, 124 patients (10.6%) in the CONV group and 34 patients (4.7%) in the CSA group developed malignancies, with nonmelanoma skin cancers and lymphomas comprising 55% and 13% of cancers in the CONV group and 65% and 3% of cancers in the CSA group, respectively. There were no significant differences in overall cancer (p = 0.41) or skin cancer (p = 0.97) incidence between non-CSA-treated and CSA-treated patients by Kaplan-Meier life-table analysis; however, CONV-treated patients demonstrated a higher incidence of lymphoma (p = 0.05). The mean (+/- SD) time to overall and skin cancer occurrence was significantly shorter in the CSA group: 37 +/- 22 versus 90 +/- 52 months (p < 0.001) and 40 +/- 24 versus 92 +/- 52 months, respectively. When the Cox Proportional Hazard Model was utilized to assess the relative importance of age, diabetic status, donor source, sex, and immunosuppressive regimen in determining cancer development, age > or = 50 years and nondiabetic status were significant independent prognostic indicators, while immunosuppressive regimen was not. Graft and patient survival were significantly greater in CONV-treated patients developing cancer than in those who did not.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Surgery, University of Minnesota, Minneapolis.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

7949545

Citation

Gruber, S A., et al. "De Novo Cancer in Cyclosporine-treated and Non-cyclosporine-treated Adult Primary Renal Allograft Recipients." Clinical Transplantation, vol. 8, no. 4, 1994, pp. 388-95.
Gruber SA, Gillingham K, Sothern RB, et al. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant. 1994;8(4):388-95.
Gruber, S. A., Gillingham, K., Sothern, R. B., Stephanian, E., Matas, A. J., & Dunn, D. L. (1994). De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clinical Transplantation, 8(4), pp. 388-95.
Gruber SA, et al. De Novo Cancer in Cyclosporine-treated and Non-cyclosporine-treated Adult Primary Renal Allograft Recipients. Clin Transplant. 1994;8(4):388-95. PubMed PMID: 7949545.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. AU - Gruber,S A, AU - Gillingham,K, AU - Sothern,R B, AU - Stephanian,E, AU - Matas,A J, AU - Dunn,D L, PY - 1994/8/1/pubmed PY - 1994/8/1/medline PY - 1994/8/1/entrez SP - 388 EP - 95 JF - Clinical transplantation JO - Clin Transplant VL - 8 IS - 4 N2 - We compared the incidence of de novo tumors developing in 1165 primary adult renal allograft recipients treated with azathioprine (AZA)-prednisone (Pred)-antilymphocyte globulin (ALG) (CONV group) with that in 722 patients receiving cyclosporine (CSA) as part of double (CSA-Pred), triple (CSA-Pred-AZA), or quadruple-therapy (CSA-Pred-AZA-ALG) protocols. Mean +/- SD follow-up was 9.5 +/- 6.4 years for the CONV group and 6.2 +/- 2.7 years for the CSA group. Overall, 124 patients (10.6%) in the CONV group and 34 patients (4.7%) in the CSA group developed malignancies, with nonmelanoma skin cancers and lymphomas comprising 55% and 13% of cancers in the CONV group and 65% and 3% of cancers in the CSA group, respectively. There were no significant differences in overall cancer (p = 0.41) or skin cancer (p = 0.97) incidence between non-CSA-treated and CSA-treated patients by Kaplan-Meier life-table analysis; however, CONV-treated patients demonstrated a higher incidence of lymphoma (p = 0.05). The mean (+/- SD) time to overall and skin cancer occurrence was significantly shorter in the CSA group: 37 +/- 22 versus 90 +/- 52 months (p < 0.001) and 40 +/- 24 versus 92 +/- 52 months, respectively. When the Cox Proportional Hazard Model was utilized to assess the relative importance of age, diabetic status, donor source, sex, and immunosuppressive regimen in determining cancer development, age > or = 50 years and nondiabetic status were significant independent prognostic indicators, while immunosuppressive regimen was not. Graft and patient survival were significantly greater in CONV-treated patients developing cancer than in those who did not.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0902-0063 UR - https://www.unboundmedicine.com/medline/citation/7949545/De_novo_cancer_in_cyclosporine_treated_and_non_cyclosporine_treated_adult_primary_renal_allograft_recipients_ L2 - http://www.diseaseinfosearch.org/result/3993 DB - PRIME DP - Unbound Medicine ER -